Belite Bio Financials
| BLTE Stock | USD 63.26 4.18 6.20% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0038 | 0.0043 |
|
| |||||
| Current Ratio | 16.43 | 24.7564 |
|
|
Investors should never underestimate Belite Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Belite Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Belite Bio ADR.
Net Income |
|
Belite | Select Account or Indicator |
Understanding current and past Belite Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Belite Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Belite Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Belite Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Belite Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Belite Bio's management manipulating its earnings.
Belite Bio Stock Summary
Belite Bio competes with Anebulo Pharmaceuticals, Mineralys Therapeutics,, AN2 Therapeutics, Aerovate Therapeutics, and Adagene. Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US07782B1044 |
| CUSIP | 07782B104 |
| Location | California; U.S.A |
| Business Address | 12750 High Bluff |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.belitebio.com |
| Phone | 858 246 6240 |
| Currency | USD - US Dollar |
Belite Bio Key Financial Ratios
| Return On Equity | -0.4 | ||||
| EBITDA | (31.53 M) | ||||
| Net Income | (31.63 M) | ||||
| Cash Per Share | 1.96 X | ||||
| Current Ratio | 35.01 X |
Belite Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Belite Bio's current stock value. Our valuation model uses many indicators to compare Belite Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Belite Bio competition to find correlations between indicators driving Belite Bio's intrinsic value. More Info.Belite Bio ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Belite Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Belite Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Belite Bio ADR Systematic Risk
Belite Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Belite Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Belite Bio ADR correlated with the market. If Beta is less than 0 Belite Bio generally moves in the opposite direction as compared to the market. If Belite Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Belite Bio ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Belite Bio is generally in the same direction as the market. If Beta > 1 Belite Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Belite Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Belite Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Belite Bio growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Belite Bio December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Belite Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Belite Bio ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of Belite Bio ADR based on widely used predictive technical indicators. In general, we focus on analyzing Belite Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Belite Bio's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.42 | |||
| Information Ratio | 0.0824 | |||
| Maximum Drawdown | 30.69 | |||
| Value At Risk | (6.09) | |||
| Potential Upside | 5.93 |
Complementary Tools for Belite Stock analysis
When running Belite Bio's price analysis, check to measure Belite Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Belite Bio is operating at the current time. Most of Belite Bio's value examination focuses on studying past and present price action to predict the probability of Belite Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Belite Bio's price. Additionally, you may evaluate how the addition of Belite Bio to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |